<SEC-DOCUMENT>0001439222-25-000114.txt : 20251030
<SEC-HEADER>0001439222-25-000114.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251030063230
ACCESSION NUMBER:		0001439222-25-000114
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251030
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		251432060

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>agio-20251030.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a68d3a3e-c458-47b6-b3f3-96de9459dc14,g:3e5c9f1b-fa42-4432-9870-38f0e9b03024,d:2bb1334da8944f20be0f4cf0aaa330b6-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20251030</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agio-20251030.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-30</xbrli:startDate><xbrli:endDate>2025-10-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2bb1334da8944f20be0f4cf0aaa330b6_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:9.9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 30, 2025</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:17pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Agios Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Exact Name of Registrant as Specified in Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36014</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">88 Sidney Street,</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge,</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02139</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">649-8600</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.775%"><tr><td style="width:1.0%"/><td style="width:3.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.562%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">AGIO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.439%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      &#9744;</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2bb1334da8944f20be0f4cf0aaa330b6_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">On October&#160;30, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September&#160;30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The information in this Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:15.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-103125xfyxex991earnin.htm">Press release issued </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-103125xfyxex991earnin.htm">October 30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-103125xfyxex991earnin.htm">, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2bb1334da8944f20be0f4cf0aaa330b6_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">SIGNATURES</span></div><div style="margin-top:9.9pt;text-indent:23.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:  October&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:    </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian Goff</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</span></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>agio-103125xfyxex991earnin.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i118d5340377242fa8711ec511bbca1ef_1"></div><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Agios Reports Third Quarter 2025 Financial Results and Provides Business Update </font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$12.9 million in third quarter PYRUKYND&#174; (mitapivat) net revenues</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">CHMP adopted positive opinion for PYRUKYND in thalassemia&#59; EC decision expected by early 2026</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">RISE UP Phase 3 trial topline results in sickle cell disease by year-end&#59; potential U.S. commercial launch in 2026</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Phase 2b tebapivat trial in lower-risk MDS fully enrolled&#59; topline results expected in early 2026</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAMBRIDGE, Mass.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, October 30, 2025 &#8211; Agios Pharmaceuticals, Inc. (Nasdaq&#58; AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;As we approach year-end, we remain focused on our two key PYRUKYND milestones &#8211; the potential U.S. approval in thalassemia and the topline results from the RISE UP Phase 3 trial in sickle cell disease. Our recent engagements with these communities have underscored the urgent need for innovation and PYRUKYND&#8217;s potential to address critical gaps in care for&#160;these serious and life-threatening diseases,&#8221; said Brian Goff, Chief Executive Officer, Agios. &#8220;We continued strong execution across our rare disease portfolio in the third quarter, including the completion of enrollment in our Phase 2b tebapivat trial for lower-risk MDS. We look forward to building on this strong momentum and remain steadfast in our commitment to delivering meaningful progress for the patients we serve.&#8221;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2025 and Recent Corporate Highlights</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Performance &#8211; PYRUKYND&#174; (mitapivat) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Generated $12.9 million in net revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the third quarter of 2025, representing an increase of 44 percent from $9.0 million in the third quarter of 2024 and a 3 percent increase from $12.5 million in the second quarter of 2025.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">262 unique patients</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> completed prescription enrollment forms, representing an increase of 6 percent over the second quarter of 2025.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">149 patients</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are on therapy in the U.S., inclusive of new starts and continued therapy, representing an increase of 5 percent over the second quarter of 2025.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">R&#38;D Highlights</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PYRUKYND (mitapivat)</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Thalassemia &#8211;  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">United States &#8211;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">U.S. Food and Drug Administration (FDA) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">extended the Prescription Drug User Fee Act (PDUFA) goal date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the supplemental New Drug Application (sNDA) of PYRUKYND for the treatment of adult patients with non&#8211;transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia by three months, to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">December 7, 2025.</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Extension was triggered by FDA request for a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Evaluation and Mitigation Strategy (REMS)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to address the potential risk of hepatocellular injury described in the original application. </font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Extension was not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios.</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">U.S. commercial launch preparations remain underway</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and the application remains under active FDA review.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">Europe &#8211;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">Committee for Medicinal Products for Human Use (CHMP)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">European Medicines Agency (EMA)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">adopted a positive opinion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> recommending approval of PYRUKYND in adults for the treatment of anemia associated with transfusion-dependent and non&#8211;transfusion-dependent alpha- or beta-thalassemia.</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">final decision</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> from the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">European Commission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is expected by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">early 2026</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">Gulf Cooperation Council (GCC) &#8211; </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">PYRUKYND </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">received approval in Saudi Arabia</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the treatment of adult patients with non&#8211;transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Commercial launch activities are underway</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in Saudi Arabia in partnership with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NewBridge Pharmaceuticals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">In the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United Arab Emirates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, PYRUKYND thalassemia regulatory application remains </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">under active review</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sickle Cell Disease &#8211; </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">Topline results from the RISE UP Phase 3 trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of mitapivat in sickle cell disease are expected by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">year-end</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, potentially supporting a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. commercial launch in 2026. </font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tebapivat </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Lower-risk Myelodysplastic Syndromes (LR-MDS) &#8211; </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.75pt">Completed patient enrollment in the Phase 2b trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of tebapivat in LR-MDS. Following findings from the Phase 2a trial, the Phase 2b trial is evaluating three higher daily doses (10 mg, 15 mg, and 20 mg) versus placebo over 24 weeks. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Topline results</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> from this trial are </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">expected in</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">early 2026</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2025 Financial Results </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the quarter ended September 30, 2025, net loss was $103.4 million dollars, compared to net income of $947.9 million dollars for the quarter ended September 30, 2024. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The net income in the third quarter of 2024 was due to the milestone payment from Servier and the sale of royalty rights to Royalty Pharma, both of which were recorded in that quarter.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Net product revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> from sales of PYRUKYND for the third quarter of 2025 was $12.9 million, compared to $9.0 million for the third quarter of 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cost of sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the third quarter of 2025 was $1.7 million.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Research and Development (R&#38;D) Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $86.8 million for the third quarter of 2025, an increase of $14.3 million compared to the third quarter of 2024. The year-over-year increase was primarily driven by increased clinical trial costs associated with the PK activation franchise. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Selling, General and Administrative (SG&#38;A) Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $41.3 million for the third quarter of 2025, representing an increase of $2.7 million compared to the third quarter of 2024, primarily driven by disciplined investment in preparation for the potential U.S. commercial launch of PYRUKYND in thalassemia.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cash, cash equivalents and marketable securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as of September 30, 2025, were $1.3 billion compared to $1.5 billion as of December 31, 2024. Agios expects that its cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to prepare for potential PYRUKYND commercial launches in thalassemia and sickle cell disease, advance existing clinical programs, and opportunistically expand its pipeline through both internally and externally discovered assets.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call Information </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agios will host a conference call and live webcast today at 8&#58;00 a.m. ET to discuss the company&#8217;s third quarter 2025 financial results and recent business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the &#8220;Events &#38; Presentations&#8221; tab. A replay of the webcast will be available on the company&#8217;s website approximately two hours after the event. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Agios&#58; Fueled by Connections to Transform Rare Diseases&#8482; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities &#8211; collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit&#160;www.agios.com and follow us on LinkedIn and X.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND&#174; (mitapivat), tebapivat, AG-236 and AG-181&#59; Agios&#8217; plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including PYRUKYND&#174;, tebapivat, AG-236 and AG-181&#59; Agios&#8217; expectations for the review of marketing applications for PYRUKYND by regulatory agencies, including the FDA and European Commission&#59; Agios&#8217; strategic vision and goals, including its key milestones for 2025&#59; and the potential benefits of Agios&#8217; strategic plans and focus. The words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;hope,&#8221; &#8220;milestone,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;strategy,&#8221; &#8220;will,&#8221; &#8220;vision,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios&#8217; current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios&#8217; product candidates will successfully continue. There can be no guarantee that any positive developments in Agios&#8217; business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation&#58; risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios&#8217; business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products&#59; Agios&#8217; results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies&#59; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies&#59; Agios&#8217; ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials&#59; unplanned cash requirements and expenditures&#59; competitive factors&#59; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing&#59; Agios&#8217; ability to establish and maintain key collaborations&#59; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments&#59; uncertainty of the results and effectiveness of the use of Agios&#8217; cash and cash equivalents&#59; and general economic and market conditions. These and other risks are described in greater detail under the caption &#34;Risk Factors&#34; included in Agios&#8217; public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.290%"><tr><td style="width:1.0%"></td><td style="width:49.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">(in thousands)</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,201&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,031&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,034&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,705&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284,330&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540,956&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.290%"><tr><td style="width:1.0%"></td><td style="width:38.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,964&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,061&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,768&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,880&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,964&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,061&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,768&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,479&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,537&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,749&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,775&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,615&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,468&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,869)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,811)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,554)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,700)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of contingent payments</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,136&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,136&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payment from gain on sale of oncology business</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,369&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,068&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,864&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income before taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,433)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,035&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,742)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,368&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,433)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947,915&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,742)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,248&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.65&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.27)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.58&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.22&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net (loss) income per share &#8211; basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,139,277&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,939,403&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,846,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,709,318&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net (loss) income per share &#8211; diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,139,277&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,432,796&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,846,173&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,581,382&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="agios_2021xlogoa.jpg" src="agios_2021xlogoa.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Morgan Sanford, Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Agios Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">morgan.sanford&#64;agios.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Media Contact</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Eamonn Nolan, Senior Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Agios Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">eamonn.nolan&#64;agios.com</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>agio-20251030.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a68d3a3e-c458-47b6-b3f3-96de9459dc14,g:3e5c9f1b-fa42-4432-9870-38f0e9b03024-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20251030" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20251030">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20251030_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20251030_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://agios.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>agio-20251030_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a68d3a3e-c458-47b6-b3f3-96de9459dc14,g:3e5c9f1b-fa42-4432-9870-38f0e9b03024-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_58c5cb24-f104-41de-8421-4acd2454855f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d2e91950-507b-4497-87ef-de721d5a8761_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_76f40221-bcd7-4f6e-b428-0cfea2dbc53d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_eb08192f-cd8d-4c0e-a306-783fb2fe1544_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a13bcf00-9962-4d90-91a7-f1f0c08f1327_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4adb341f-40b1-4b2e-a6f5-4815e24dcea4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c6b4c78a-775b-4244-be87-c86f9b6ad547_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_35755924-e227-45a3-816b-6daf742174d6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8c9b6d8b-0393-4dc6-addf-1ce0e456a8ac_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_809a476a-01b6-450e-a504-157c21d23293_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_28eb6391-b844-46a9-bb6c-2a046f88b84e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f94002f2-ba34-472f-935a-62071af02a1c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c7e2d716-1104-41eb-937b-6def8b8f147e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3fe390e8-8ff3-4945-93aa-cfe49d95c36d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3c4140c0-afa8-4430-8091-d20e31fccc3d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dd08b1c5-295c-4fea-868d-d65a385c06bb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_88425486-d60e-432f-8bc4-9a7552618d6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f47a07c7-28c3-4280-8730-a2d9b7b42d86_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b8f9b059-98cb-4fb6-97e1-5e1b8b6febc0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f0fae73d-4a21-4eee-a7b5-879acc542227_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f8a440bd-2d6d-47f3-a412-a8cb873e2e0b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46c81709-173a-43fc-a9f0-c63abd665373_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>agio-20251030_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a68d3a3e-c458-47b6-b3f3-96de9459dc14,g:3e5c9f1b-fa42-4432-9870-38f0e9b03024-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="agio-20251030.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://agios.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c67263f4-3f5c-48aa-8a38-8f71f7a58871" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_AmendmentFlag_c67263f4-3f5c-48aa-8a38-8f71f7a58871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_91ceb29c-24a5-4a02-8573-9d4f70e34736" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityCentralIndexKey_91ceb29c-24a5-4a02-8573-9d4f70e34736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0b3b64d4-4d15-43a7-8a10-39bef9bdca86" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_DocumentType_0b3b64d4-4d15-43a7-8a10-39bef9bdca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_493e4e05-5826-45f0-8fa7-79f8b895d2dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_DocumentPeriodEndDate_493e4e05-5826-45f0-8fa7-79f8b895d2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_29f4b020-6713-4286-96e1-fbef83ba7d70" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityRegistrantName_29f4b020-6713-4286-96e1-fbef83ba7d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8ccb613d-cfe3-4071-9a6f-dabf3bed2542" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8ccb613d-cfe3-4071-9a6f-dabf3bed2542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_da8855e1-867e-4f48-9756-d2edd73576a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityFileNumber_da8855e1-867e-4f48-9756-d2edd73576a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a6d4c5f0-3b5e-4105-945e-935e972a058d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityTaxIdentificationNumber_a6d4c5f0-3b5e-4105-945e-935e972a058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4169e846-a6c3-40c1-8935-ab0d24222543" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityAddressAddressLine1_4169e846-a6c3-40c1-8935-ab0d24222543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7f2dad11-6c31-4fea-9ab5-4beb7421989d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityAddressCityOrTown_7f2dad11-6c31-4fea-9ab5-4beb7421989d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e756a1c1-7363-465a-b43b-9558264fdc44" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityAddressStateOrProvince_e756a1c1-7363-465a-b43b-9558264fdc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a367c79d-7618-44e6-ae02-51b21770431f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityAddressPostalZipCode_a367c79d-7618-44e6-ae02-51b21770431f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8841e24-c174-4739-8154-c13480c3a671" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_CityAreaCode_c8841e24-c174-4739-8154-c13480c3a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_18cd594f-00d7-44dc-a257-834618735a90" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_LocalPhoneNumber_18cd594f-00d7-44dc-a257-834618735a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fca00493-2e3b-4ba0-83cb-99fea4251ad9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_WrittenCommunications_fca00493-2e3b-4ba0-83cb-99fea4251ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fbbb2d9d-b2d0-4620-99ae-e20b6d41936f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_SolicitingMaterial_fbbb2d9d-b2d0-4620-99ae-e20b6d41936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_aafc2563-0b0f-4ac4-9461-ddd6dcf29fa5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_PreCommencementTenderOffer_aafc2563-0b0f-4ac4-9461-ddd6dcf29fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b02166df-438e-4fc2-9bf7-5341d84c310e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b02166df-438e-4fc2-9bf7-5341d84c310e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_98daea9b-7755-4d24-94dc-11fdeaaecb25" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_Security12bTitle_98daea9b-7755-4d24-94dc-11fdeaaecb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_645740b8-5db9-4ad4-816f-d57ddbbb2b7c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_TradingSymbol_645740b8-5db9-4ad4-816f-d57ddbbb2b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fa8349dd-228e-4892-a25d-d008f0e7ad73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_SecurityExchangeName_fa8349dd-228e-4892-a25d-d008f0e7ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eb36a3e5-83ff-4596-aa9a-8c8b03790945" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01a29b06-93c3-444b-b80b-27fa6110ca14" xlink:to="loc_dei_EntityEmergingGrowthCompany_eb36a3e5-83ff-4596-aa9a-8c8b03790945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>agios_2021xlogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 agios_2021xlogoa.jpg
M_]C_X@) 24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B '
MSP &  ,       !A8W-P05!03     !N;VYE
M]M8  0    #3+4%$0D4
M                      IC<')T    _    #)D97-C   !,    &MW='!T
M   !G    !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB
M5%)#   !Y     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'
M !1T97AT     $-O<'ER:6=H=" Q.3DY($%D;V)E(%-Y<W1E;7,@26YC;W)P
M;W)A=&5D    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                                    6%E:(        /-1  $    !
M%LQ865H@                     &-U<G8          0(S  !C=7)V
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MP\3%QL?(R<K4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,   $1 A$
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M%[BN1$7O*IS?@.<,J9HCX7+>)4-<VU_7$\<JHGEFL<KFKSHY$5.4]9RU&1C
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MQ<+-';5=,>I%F[E Z:R*I!^ Q3 (9I>QDC%CD1',5+*BI=%3I13<BEE@D;-
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MC7%EL-T8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, __T=_& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# /Z<A(,(EB\E)5\SC(R/;+/7\C(.46;%BS;)F5<.WCMP=-NV
M;()$$QU#F*4A0$1$ #-<<<DKTBB:KI'+9$1+JJKN1$3:JKS(;4TT--"ZHJ'M
MC@8U7.<Y4:UK42ZJY5LB(B;55=B(<1N7GCJ<9M%>ZE4T<E]5&[%;><V];KS_
M -SM50[PO4G>^O'DN36;R3&*H5.%0=-ER@8@O4#^T.:,IZ$<R8WJU6-KXG8>
MNVSTO.Y.B/9J<UY%:Y-^HY#JEI)ZK?(>4N$P[*:>+F-MNFM&[5I&+Y:>R\+;
M>B0->QVU.%8N[,URA\37F'RS-(QNP]H/:[0Y Z@?&NUL5Q3*(5JH'06$BT9N
MUYNUM0,'< 33Z2$I_:42@  '9#+.C?*.5=63#Z9LE<WV--:26_.BJB-8OQ&U
MG2=$,_Z>=)ND97P8UB#H,(?]$E+>"GLOD7(CEDF3E]?R2V7=;9;X#S.SAP8
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MZ=+55.D[A98SGE7.E#XHY5Q"EKJ3E6)Z.<Q5Y)&;'QN\K(UKK;;'L.6@R88
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MN6^I;TS9C1LKL-9A]*_R=9*R&WM43>$J&]^%.BYTGUEZ-[.K%0=;DY.1,>8
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ME7ZQS%3D48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M?^5C!A]?\UX0\U'AZNQ0WI28DB<RU+W]@N[_ $6,2(UEDB%/W*O(1-!P1-,
M"/<J'$X=>LYZ!XI->OR8_4DVJM-([L5Z(I5VMZ&R*J77QQJ)8[NZ*NK(J(."
MP;2I%PL.QJ5\#.S3RU13M2STYWP(UR(GC,CE533EK3:.NMR4Z*V#JJZUR_TN
M;3$\;8ZO*-I6.6.0"^>T54;G,=G(LSF['#58J;ELH D5(0X"4.M>)89B&#UC
MJ#%(9(*QF]CVJU>A=N]%Y')=%3:BJAWUP+,&"9GPR/&<O54%9A<J=C+$]'M7
MG153BN;N<QUG-78Y$78?O<H2\# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI&#H<A1 0R@>Q\:ZKT5%Z36BHNU#UW-)]& , __5W\8 P!@# & , 8 P!@#
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MSF$1$1$1$1RO-L_CP!@# & , TI^%7Z1GR)X<2E?U/RGD[;R3XQ][>.(XE9
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M & , 8 P!@# & <Q_$#\4#2W!B$7KZ@M]C[XDX\KBN:IB9!-(T6F[1,=E/[
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M0[5"=PD4)U*8!*(@-)74%%B=,ZCQ"&.>D>G9,>U'-7NHJ*G<7>G(7+",9Q;
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M+KT73Z"DJ7Y>[<WY^(W+!B/P9]M0J8^*:)\H36, \NW;N.@\>M0[)WEM*8+
MZ\U339Z\VZ4["JKHP]?8+/W"$>U,HD+^6?BD#=FU(8%'3M5-$G4YR@.IC'/<
MC&\95/BK9+DD'Q >;FT/$%Y1[%Y);/<+MC6-\,30J<#Q1U%ZWUI$+N$Z?18?
MN[$03C&2QEGJZ::(2$JX=/3$*HX.&9-!"V"-(V]_I4IG+K+<^+<W32?1_$[B
MGN?FGO>C\>-#5E6QWR[OR)>>J1V2OU.!052";NMRDVC1Z,'4*XV6!5XZ%,YO
M:1)(BKA5%%31+*R%BR/W(?4156R%-OPN_!PXR>&A1XQ[7H:.V9R1DXI-*_\
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ML=,1[V)EV#*5BI)JNQD8R2:H/H^08NDC(NF;UDY35;.FKE$XD434*8ARB("
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MLA5<G-T1Z#2UL2RTZHWC)M\'I&MBV<5/,QPJ1@# & , 8 P!@# & ?_2W\8
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MV/1KV+L<U%2QZ1EN+X, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MJ5%,]42>G>J;GMY6*J+P<K;LDLME1S7M;]>YB1R4, 8 P!@# & , 8 P!@#
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MW162/Z:YQL<\C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M6IA6#Y$:!VQIYV1R+5!W>:5.0\#**E O4T!:%6AJU8VPB;H"S!VY1$W4 -U
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MI5;K[@[M85A.%X'0185@U/#2X;"W59%$QK&-3F1K41$Z>55VKM/U.4I<!@#
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MUAZ7LAV9M%UW;*A$_*;QLV;Y PK^PW'84J8!Y;.86-VHE1<F3;K=2M)VB&;
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M\"[=C[2'/(U;7;!RD)1'Y652 >A@,4,?Q!^M4JG,B)ZO"5,:6:=]LHC6, 8
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MQ)X6M<]Z=]O<Z./\6ZJK0GA:*D>*25<J7[&"FJ'<VY\D<<:WY+/5-BWMLO\
M$VQO2.=&Q::Y-3\>MI75P0QDT5KY8*KKEDIT#IZP7W#4V4[.EYGM*0R:1SDZ
M=>PPB 9GAW4\XW*J+BN(4L+?KDU\J]SLN!3S5[_+Q5CG5OY2IT5,NX+B%4_<
MBU$D5,WN^N^NEMS(J(JIOLNQ.=&V?2!N:%U379:V@=4Z89G _J\C#UM>ZVI
MQ^H *DA>'DK5UP3* =H>XA/?=1,)@$ +R%A6@7)U&J/Q&2JK'\J.>D;%[T:-
M>GXD7W/"68^K+THXJU8L"AP["XEW.9$L\J=UT[GQ+;D]<)TWV(G+/<7+CDYR
M .N&X]Z[,OK%P/<>!E[3(I50AN_S.YM3X]5E5F8B?H(BBS)U[0_!0Z<G81E3
M+6 HGB10TT#T\DUB:_?D6[U[[E.ON9M)&?<Y*OP)\7KZR)WL-\KDAY]D+5;$
MWVUB<G,EOG7,@,)& , 8 P#ZDXZ<+>3O*V2(ST=J*T6V-!R+5]<%6Q8.AQ*I
M.IEDY.ZS9V%<;N4DRB;U8K@[M0 Z)I'-T <9S#G'+65H]?&ZN**2UTCOK2N]
MIC;=ZITV1J<JH<@9)T6Y]TB3I%E/#:BI@UK.F5.#IV+RZ\[]6)%1-NKK*]?(
MM5=AH[XI>CV:ZJBD7:N6U^4V9+H"1RMK'7;B3K]"(J'ECZI-6]5./N-C;?.N
MI6:4((&Z>_4)U W7C-.GW$*I'4N5($IHEV<-*B/E[K8]L;%]J63N(N[O!H[Z
MB_!,.='B&D>L6OJ4VK2TRNCI[\SYE1LTJ>T)!MY7)=%T$:SU5K73538475%&
MJ^O:A&!\J0%3AV4-'@J)"$5>.$V:29GTBY[ %9RN*CA<_OE#F,(B/ N)8IB.
M,53J[%)Y:BK=O<]RN7N)?<B<B)9$Y$0[EX#E[ LKX<S",NTE/18;'NCA8UC;
M\KELB:SE\DYUW.7:JJNT_?Y0%Y& , 8 P!@# & , 8 P!@'\:J22Z2J"Z2:R
M"R9TED52%42524*)%$E4S@8BB:A#"!BB @(#T'/J*K51S5LY#2YK7M5CT16*
MEE1=J*B[T5.8RO>*/X+(QA9_D-PRK*JK /.EM@:"A6QUEF/M3%U/ZECVR)E5
MF0!W+NH+J8Z/OS,.J8D9I=GM&6F/A5CR_G"5$DXL54Y=_,V=5Y>1LO+LX3;=
MZQ\=4!U+7 )-G31? JP[7U&'L2ZMYY*-J)=6[W/I]Z;5ANEHFY@#%,4PE, E
M,41*8I@$#%, ]! 0'V@(#G9?>=!5146R[S_7!\& ?[%,8I@,41*8H@8IBB(&
M*8!Z@("'M 0'&\^HJHMTWFG+PO?&J5@@KW'OF;9574*'JL-0]_SCM9P]B1,<
M$&4'ME^X,JH\B@ Y4T; H;S&@%#W0$Z0G=H=:])FAM)^$Q_)\:)-M=+2M2R.
MY5= B;G<JQ)L=[#LMF.[ZZ >JG=2<!DO2A.KJ78RGQ&155S.1L=8Y;JYFY$J
M%6[+>OKMO(S54T=M7[5L^8N6[UD];HNV;QHLFX:NVKA,JS=RV<(F.DNW72.!
MB'*(E,40$!$!SJ^]CHW*QZ*CT6RHNQ45-Z*G(J$A<<D<T;98G-=$YJ*UR*BH
MJ*ET5%38J*FU%38J']C-)K& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# /GWDERBTEQ-UX\V5N^Z,:O"I@NC#193)
MN[1<)5%,JA8&GU\BI'L[+*=Y>X"=J#8AO-<*HH%.J6_Y=RSC6:L03#<%A=+-
MLUG;F1M[:1^YK>[M5=C4<ZR+AF><_P"5-'."NQW-=4RGI4NC&;Y9GHGC<,=]
M:1Z[+V[%J+K/<UB*Y.&E/:<H?&NMGN_L%.R\=/#GKTV8S&EPK\S*W[Q?0[A-
M9HF_E3M>R=12>D(JY=>4:%BU4P09INGZ*KQ/FRK?EG0U2\!0<'B&D*1FV1R7
MCID<FVS;]CLNB-OPCT76>K8U1B]3,,CS_P!51B/7F-)/@FA&"7L8&.U9J]S%
M141S[>O$1UE<^RP1*FI$DDS72MT/4&@TS5M,K>O->5N*J%*J$4WA:Y7(5N#6
M.BXYJ ]B21.IE%555#&4664,=9PL<ZJISJ',8>O]?7UF)UDF(8A(Z6ME<KGO
M<MU<J^JR(ED1$1$1$1$3NI@^#X7E_"X,%P6".FPJFC1D43$LUC4Y$YU7>YRW
M<YRJYRJY55?U^4A<A@# & , 8 P"/KXDMRD-@>(3S?MTF945Y;E=OP&Z:R@+
M*-(J.V=9HJ$CA5*1,%"Q<,Q;MBF[2]2I /0,RBG35@8B=JGG%*Y;N4^*,W32
M=MO1V]7Q^T?%QXO)3#,SZ)H)MD[0<H@@*I$Y"EZSM;RJ/%%/:5L6/NJ\:N4Y
M@$!.F4@=#' P4E<[5I76WK9/--<:7<5*\QTJ1@# & , 8 P"35XTO)^,Y<>)
M;RAVK69)*6HT9<F^KM?OFBQG$:]J>IHAC04)F)5,8PGC+5*P;N82$.@&"0Z@
M =>@9+21K%3M:N^UU[^TIGK=USEGE0:#]OK/[6/K_P#8[U3\_P PSX[BKW#Z
M6JLQ,JQ@'*SQI^(3KFKX<G(35->BC2VQJS!(;?U0V09B^DG%^U<HI8V\-#-R
M@)S2]TKB4E7T1+[0&6']8&II)>!G:Y>*NQ>XOJN:7I=MN4DXYDA2C -='HKW
MB*1NG]OW#@7M*>2C:5O^6"Z:1?23DJ#"*W:RC&\?-U %5A*B@;9]7BVP-.XY
M0-*PZ#5$AUY  &V8C!K-29N]N_N>D;L;K+JF_G+*;XP!@# & , 8!EZ])O\
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M7AB\?:UR"NNKKAM>#L6V:]JE2$IDA&Q;Z(<V*J7BSM[!(/)9-1FG%(FI0LQ
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MJR=NB(T^C=O/?/74ONOHYF6(GGZA0 KB[44QV<-/&[^XZCEHI&R2YS=572@
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M/WV4!>!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M'JS55+(NU%5-B\RV\%=-'3%PJT>MG#-T@?RUVSI%1NX1.'M$BJ*I2*)G !^
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MCV78[;QPTYW:$YOTCXI=43_J=KB6K<]XU?/J(-;O2G2HE3$[QB10Q): 77,
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M\%*-UX> WYS'AH^P;!*9&8IVDGWJTM7Z8OU\UK,["$IW$?9;24W11*- 56#
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MO79ZUJ+VU'> ^Z[><^7]P>D8>$MJ1BY5;<C7FV9EN7N3K.G]=7JSOG@=G?\
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M5R@I2L6ZHS<K6K16YQDO&S4!8(-\O&S$-+1[HB;EC(QD@V41624*4Z:A!*(
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M0%"QPC&81%$BXF6(D*;P.T#B)@#X?;US$W)JN5.92L/V6? , 8!RL\4OPFM
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M;#%L621;.FG>B<>:2R*]V^R;&,1;,:UNP^DLQTSD8 P!@# & , 8 P!@# &
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M3A"&64\I(I9Z)J[Z%5,HIT*4".#=1$/HPZ[Z5$"[GM\*&G5<G(I_QZ[X=7B
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MS[:A4Q\4T3Y0FL8 P!@'RQR]X7<<.=.I7^F>2VN8R]U194[^#D!$8ZVTB?\
M),BA9Z+:6H%E:S.H)F[#'1/Y+I$3-W*:[911$^Y%+)"[7C6RGQ41=BF!OQ$O
M1H>8'%AY/WWC UE>6NC&YWC]%K5XY(-ZU"**<ZB36Q:[9=%;R=LD8J?KE:(Z
M6<F*=92.9)^P+U!B$4G8R=B_S/#[DV'1JF[:AFWDHR2A9%]$3$>^B9:,=+L9
M*,DFB["1CWK50R+EF^9.DTG+1TW6()%$U"E.0P" @ AE>BWVIN-!_1P?!@#
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MW.!#LF3-9,5U+-4USYNPC[&/S5-YL:)M7>:2,H#<& ?_U-_& , 8 P!@# &
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MQ7*=?3UU'LOP;NS8J[FRQNM)$[RLC6NMMM8]HRS&4C & , 8 P!@# & , 8
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M55=JJNU5.^M-34U%3QTE'&R*DB8C&,8U&L8UJ6:UK6HB-:U$1$1$1$1+(?\
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M<J*K52[5MV35NUR;%14V'?'B_P"D)[BI98VN<I*!';@@TA10<7ZDDCJ=L5%
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M:)Z3Y8L/#X\]EI:V9$=.^^]K-EH8E7V'':Z(WA'2.:CC[VS!3F 8 P!@# &
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M$]5C2];-).N9(4HP#;SZ(/QK<I-^6/+Z7CC$;NQK/'2A28E*'G^KF9['VHV
M3%\P4B*'J(D,4>PQRJ /42!VVG%).+$G=]!/1-Z)-ZFVC+0;PP!@# & , 8
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MJ& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# /_]??Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MZ 8! W4PY=0:(]'U!9S</;+(G+*^22]N=KGZG@:G@.,\9ZIG37C2.9)C4E/
MM^QIX8(+7YI&1I+W+R*J;[WVK\*;!W/N#;3@KO:FUMD;*<IF Z:]^O%FMZJ1
MB@8"BD>P2<@*78!Q O;T[0'H'LS-Z#!\(PINIA=+3TS>:*-D?Z@U#B+&<T9F
MS&_A,PXC75\B;EJ)Y9E3N<(]UN\>:9<BQ# & ?MM>ZVV!MJU1M&UC2[-?[A+
MG$L?7*E"OYV6<%*8A57'J<>@NJBR; <#++J 5% GOU#%* B%%B&(T&%4KJW$
MIHH*1F]\CD:U.BZVVKR(FU5V(BJ7;!<"QG,>(LPG *6HK,3DXL4+'2/7G75:
MBJC4WN<MFM3:JHFTT8<._1];-.DB+MS*MRE0CSBD\^,SK]^Q?V=9,I^\&=OO
M:(OH.&!04^BK:)*_4.BI[UZV5 0+U\S=I[IH%?190B2:3=UQ*BHQ.F.+8YW0
MK]5$5.(Y-_=K1EU&=?5I%BND^I6FAV.ZRIW-=*OE9JA-:-G2V%)%5J[)6.39
MIHTUHO4''NF,]?:6U[6]=5)ET,$97V7E*O7 !VB_FI5R=Q,6"5.4>AW;YPX<
MG   R@] Z=;L8QO%L?K%K\9J)*BK7R3EW)S-:EFL;Y5J(WH.^66,I9:R7A;<
M&RM1046&M\C&VRN7MGO6[Y'\[Y'.<O*IZQEJ,B& , 8 P!@# & , 8 P!@#
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MSIQIHUT=M504 ?6?.6DRD*0D:X5M.(526X"->[[CW/R)O1L\DIMTRT&\, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , _]#?Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MXVU5*EZ/UG5M=01")@Z+!L ]U9A5(H%([L5A>'=3]D?@4 #UA^Y<+=H '=T
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M%)LV;))H-VZ"9$4$$$2 FDBBDF!4TDDDR@4I2@ % .@>S+0;Q_+@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MC;9JF:?CKV/,F[U=TW4:C=QTHRG-0P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P#__3W\8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M#Y:Y+?>%?N8_[@<R?+GL;VS]V./L]_1+]Y?WF?+69,<?'I&H?M8]7_7T[_/:
M]RW8M\XZ7N)YZ%]RU\YRG]J7]1<= LP,YE& , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
; 8 P!@# & , 8 P!@# & , 8 P!@# & ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Agios Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="agio-20251030.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="agio-20251030.htm">agio-20251030.htm</File>
    <File>agio-20251030.xsd</File>
    <File>agio-20251030_lab.xml</File>
    <File>agio-20251030_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "agio-20251030.htm": {
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20251030",
   "dts": {
    "inline": {
     "local": [
      "agio-20251030.htm"
     ]
    },
    "schema": {
     "local": [
      "agio-20251030.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20251030_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20251030_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://agios.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20251030.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20251030.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001439222-25-000114-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-25-000114-xbrl.zip
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M4>*W+!0QB\2U"!.A2FH\##6^GGW_>,) JP6,)* OIR1@WZM75::^G)UH,O&
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M1J^XULHU[TLB;@F?<]JT'\D175AN8Y?;U"K[ R",!,:B0),!,-%H2G=8#59
M+DM"K0N&'%@E =I%RI61T) DT0 ?#P7R E [Y2K8/T6/680">VT?J]Q&8PE>
MFQ=A1.FBMD&.'?"QT5,1N=<0V+1JQQH4))U,-'\%?E]4XB'E6D)DYHQ!B5*
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M2%, //EK-%=@LB!9"^"JI;#I*;<D;3]%0#J!(?=VRN3,O#<+A^EM9JP1?2=
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MA,5JB%C\"0L6S1Z_ZTEO O\9QJ/@P_\#4$L#!!0    (  XT7ENKJP=C41
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M"_W[ LKV/@+*EQ')+M)+<RCRV_2.R2/WG8$)FHQ YU)0OYC,#:J/45#X-(I
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M:6XN:'1M4$L! A0#%     @ #C1>6ZNK!V-1$   #'X  !$
M ( !8A\  &%G:6\M,C R-3$P,S N:'1M4$L! A0#%     @ #C1>6[NI&Z]N
M @  + <  !$              ( !XB\  &%G:6\M,C R-3$P,S N>'-D4$L!
M A0#%     @ #C1>6_77XWO]"0  ?50  !4              ( !?S(  &%G
M:6\M,C R-3$P,S!?;&%B+GAM;%!+ 0(4 Q0    (  XT7EL$2Z6)L@8  !4Q
M   5              "  :\\  !A9VEO+3(P,C4Q,#,P7W!R92YX;6Q02P4&
2      4 !0!0 0  E$,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>agio-20251030_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agio-20251030.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2025-10-30</startDate>
            <endDate>2025-10-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001439222</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-10-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Agios Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36014</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">88 Sidney Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">649-8600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
